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Objective. To develop a simple and efficient method for producing homogeneous populations
of monocytes and macrophages from human embryonic stem cells (hES).
Materials and Methods. Human embryonic stem cell lines KCL001, KCL002, and HUES-2
were differentiated into monocytes by coculture-free differentiation with two growth factors
using a three-step method. The method involved embryoid body (EB) formation in hES media,
directed differentiation with macrophage colony-stimulating factor and interleukin (IL)-3,
and harvest of nonadherent monocytes from the culture supernatants. hES monocytes
(esMCs) were analyzed by microscopy, flow cytometry, transcriptome analysis, and tested
for the ability to differentiate into macrophages. hES monocyte–derived macrophages
(esMDM) were analyzed for phagocytosis and endocytosis by microscopy and flow cytometry,
cytokine secretion by multiplex cytokine assay, and for interferon (IFN)-g and IL-4 activation
by flow cytometry.
Results. Homogeneous esMCs (O90% CD14-positive) that did not require any additional pu-
rification steps were produced after 18.7 ± 7.7 days (mean ± SD, n[ 19). Production contin-
ued for several months when growth factors were replaced, with a total yield of 3.43 105 ± 2.0
esMCs (mean ± SD, n[ 9) per EB. Transcriptome analysis of the esMC and the esMDM re-
vealed a distinct myeloid signature that correlated with primary adult blood–derived mono-
cytes and spleen tissue samples but not with other tissue samples tested. We found that esMCs
and esMDMs expressed well-defined markers of the mononuclear phagocyte system including
PU-1, C/EBPa, EMR1, and EMR2, MPEG1, CD1c, CD4, CD18, CD32, CD33, CD68, cathep-
sins and serine carboxypeptidase. Finally, esMCs differentiated into functional macrophages
that could endocytose acetylated low-density lipoprotein, phagocytose opsonized yeast parti-
cles, secrete specific cytokines in response to lipopolysaccharide, and be activated differen-
tially with IFN-g and IL-4.
Conclusions. We have developed a simple and efficient method for producing homogeneous
populations of monocytes and macrophages from hES cells. esMCs have a myeloid signature
and can differentiate into functional macrophages. The method should prove useful in answer-
ing experimental questions regarding monocyte and macrophage development and biol-
ogy.  2008 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.
Experimental Hematology 2008;36:1167–1175The mononuclear phagocyte system consists of cells de-
rived from progenitor cells in the bone marrow. These my-
eloid progenitor cells differentiate into monocytes, which
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they differentiate into macrophages [1]. Mononuclear
phagocytes as they appear in tissues share certain features,
including morphology, expression of enzymes and recep-
tors, endocytic and phagocytic capability, and secretion of
cytokines in response to pathogen stimuli [2]. However,
mononuclear phagocytes are phenotypically and function-
ally heterogeneous as a result of cellular differentiation,matology and Stem Cells. Published by Elsevier Inc.
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such as the T-cell cytokines interferon (IFN)-g and interleu-
kin (IL)-4 [3].
Monocytes and macrophages play key roles in various
diseases including atherosclerosis, sepsis, cancer, tubercu-
losis, and HIV-1 [4]. Although advances in gene knockout
technology in mouse have led to major contributions to
the knowledge of murine macrophage development and bi-
ology [5,6], the human system differs extensively from
mouse and remains poorly understood due to limitations
in current technologies.
Several methods have been developed for generating hu-
man primary monocytes and macrophages for in vitro stud-
ies, but methods differ in cell yield, purity, and activation
status of cells, resulting in contradictory findings [7]. Fur-
thermore, the tendency of monocytes and macrophages to
remain in a G0-state and to degrade exogenous macromol-
ecules makes them inherently difficult to transfect. To-
gether, this limits the ability to genetically manipulate
human monocytes and macrophages and to investigate their
development and biology.
Pluripotent embryonic stem (ES) cells offer an attractive
alternative to overcome these problems. Previous work has
indeed shown that mononuclear phagocytes, including mac-
rophages and dendritic cells, can be generated from both
mouse [8–12] and human ES (hES) cells [13,14]. However,
current methods using hES cells are complicated by the re-
quirements for cocultures with cell lines, use of complex
cytokine cocktails and additional purification steps, which
limits their use in studies requiring high numbers of homog-
enous cells.
Here we describe a simple and efficient method for pro-
ducing homogeneous monocytes from hES cells that does
not require additional purification. Following differentia-
tion with macrophage colony-stimulating factor (M-CSF)
and IL-3, a homogeneous population of CD14-positive
monocytes is produced. These hES monocytes (esMCs)
have a distinct myeloid signature and are capable of differ-
entiating into functional macrophages. The method should
prove useful in answering experimental questions regarding
human monocyte and macrophage development and biol-
ogy especially when combined with specific genetic modi-
fication of hES cells.
Materials and methods
Culture of hES cells
The human ES cell line HUES-2 (passages 16–38) was obtained
from the HUES Facility, University of Harvard [15]. The hES
cell lines KCL001 (passages 5–25) [16] and KCL002 (passages
12–40) were derived at the Stem Cell Biology Laboratory, King’s
College London. Work on all three cell lines was reviewed and ap-
proved by the UK Stem Cell Bank Steering Committee. The gen-
eration of hES-derived monocytes and macrophages was
confirmed using all three cell lines. Data presented here werefrom HUES-2 ES cell line unless otherwise indicated in the figure
legend. HUES-2 ES cells were cultured at 37C, 5% CO2 and at-
mospheric O2, and maintained on mitomycin C-inactivated mouse
embryo fibroblasts (MEF) in 0.1% gelatin-coated six-well tissue
culture plates containing 2 mL hES medium. hES medium con-
sisted of knockout Dulbecco’s modified Eagle’s medium (Invitro-
gen GIBCO), 10% KO-Serum Replacement (Invitrogen GIBCO),
0.5% albumin (cat. no. 534021-4l; Sigma, St Louis, MO, USA), 2
mM Glutamax-I (Invitrogen GIBCO), 1% nonessential amino
acids (Invitrogen GIBCO), 100 U/mL penicillin and 100 mg/mL
streptomycin (Invitrogen GIBCO), 0.055 mM b-mercaptoethanol,
10 ng/mL basic fibroblast growth factor (R&D). Medium was
changed daily by removing 1 mL and replacing with fresh hES
medium. hES colonies were typically passaged weekly after as-
sessment of size and morphology. Undifferentiated colonies
were microdissected using a heat-pulled glass pipette and colonies
transferred to MEFs that had been conditioned with hES medium
overnight.
Differentiation of hES cells into monocytes
For embryoid body (EB) formation (Fig. 1A, Step 1), hES cells
were removed from feeder cells either mechanically by microdis-
secting hES colonies into 0.2-mm–diameter patches, or enzymat-
ically by dissociating colonies using trypsin for 2 minutes. Patches
were transferred into six-well ultra-low adherence plates (Corn-
ing) in hES culture medium and cultured for 3 days at 37C.
For differentiation (Fig. 1A, Step 2), 50 to 100 EBs were trans-
ferred into tissue culture T25 flasks containing 10 mL culture me-
dium supplemented with M-CSF and IL-3. Alternatively, 20 to 50
EBs were transferred into one well of a six-well plate in 4 mL me-
dium. Medium was replaced every 5 to 7 days. Culture medium
consisted of Advanced Dulbecco’s modified Eagle’s medium (In-
vitrogen GIBCO) and 10% fetal calf serum (Invitrogen GIBCO or
Hyclone), supplemented with 50 ng/mL M-CSF (R&D), 25 ng/mL
IL-3 (R&D), 2 mM L-glutamine (Invitrogen GIBCO), 100 U/mL
penicillin and 100 mg/mL streptomycin (Invitrogen GIBCO), and
0.055 mM b-mercaptoethanol. For monocyte harvest and continu-
ous production (Fig. 1A, Step 3), the supernatant was removed and
replaced with fresh culture medium. Viability of esMCs was con-
sistently greater than 90% by Trypan blue dye exclusion.
Isolation of blood monocytes
Adult human blood was obtained from anonymous donors through
the UK National Blood Bank Service, and tested negative for HIV-
1, hepatitis B/C, and syphilis. Peripheral blood mononuclear cells
were isolated by Ficoll-Hypaque (Pharmacia-Amersham) density-
gradient centrifugation from heparinized buffy coats. Monocytes
were isolated by CD14-positive selection using anti-CD14
magnetic beads (Miltenyi Biotec) by following manufacturer’s
instructions.
Histochemistry of monocytes
Cytospins (400 rpm, 5 minutes) of hES monocytes were dried
overnight. Slides were then sequentially fixed in methanol (30 sec-
onds), stained with methylene blue (30 seconds) and stained with
eosin (2 minutes). Slides were washed with water and images
taken using a Nikon Coolscope.
Differentiation of monocytes into macrophages
Human ES cell-derived monocytes or blood monocytes were dif-
ferentiated into macrophages at a density of 1.5  105 cells/cm2.
1169K.R. Karlsson et al./ Experimental Hematology 2008;36:1167–1175Figure 1. A three-step method for the differentiation of human embryonic stem (hES) cells into monocytes. (A) Human hES cells were removed from mouse
embryonic fibroblasts either by microdissecting colonies or treating with trypsin. Patches were cultured with hES medium in suspension for spontaneous
embryoid body (EB) formation for 3 days (Step 1). Adherent EBs were next differentiated in macrophage colony-stimulating factor (M-CSF) and interleukin
(IL)-3 (Step 2). hES monocytes (esMCs) were produced and harvested from the supernatant of cultures around day 18, and growth factors replaced for con-
tinuous esMC production (Step 3). Arrow head in Step 3 show part of an EB. Images are from hES cell line KLC002 and representative of KCL001 and
HUES-2. (B) Eosin-Methylene blue staining of harvested esMCs from cytospins. (C) Morphology of esMCs by transmission electron microscopy. (D) For-
ward-side scatter plot of esMCs from hES cell line HUES-2. (E) CD14 surface expression on esMCs from hES cell line HUES-2. Histograms show antibody
staining (in black) relative to isotype-matched control (in gray). (F) Accumulated esMCs yield and production kinetics from separate experiments from hES
cell line HUES-2. Mean number of EBs used per experiment was 30 6 13 EBs (range, 19–55, n 5 9). (G) Phase contrast image of hES monocyte-derived
macrophages (esMDMs) differentiated in M-CSF for 7 days and the esMDM expression of CD68 and CD163. Histograms show antibody staining (in black)
relative to isotype-matched control (in gray). All scale bar units are in micrometers.Culture medium consisted of RPMI (Invitrogen GIBCO) and 10%
fetal calf serum (Hyclone), supplemented with 100 ng/mL M-CSF
(R&D), 2 mM L-glutamine (Invitrogen GIBCO), 100 U/mL peni-
cillin and 100 mg/mL streptomycin (Invitrogen GIBCO). Medium
was typically changed every 3 to 4 days by removing half and
replacing culture media with twice the final concentration of
M-CSF.
Microscopy
Phase-contrast images were obtained using either an inverted-
phase Axiovert 25 (Zeiss) or an Elipse TS1000 (Nikon) micro-
scope. Images were processed using Corel Photo Paint and Corel
Draw software.For TEM and SEM, 3  105 or 5  105 cells were grown on 13
mm2 coverslips in a 24-well tissue culture plates and fixed in 2.5%
glutaraldehyde, 2% paraformaldehyde, and 0.1% picric acid made
up in 100 mM phosphate (pH 7.0). For TEM, coverslips were re-
moved and remaining adherent cells postfixed in 1% osmium in
100 mM phosphate (pH 7.0) solution for 1.5 hours at 4C, stained
en bloc with 2% aqueous uranyl acetate for 2 hours at 4C in the
dark, dehydrated with ethanol and released from the plastic using
propylene oxide. The released cells were pelleted and embedded
in epoxy resin. Ultrathin (w70 nm thick) sections were stained
with uranyl acetate and lead citrate and examined in a FEI Tecnai
12 electron microscope.
For SEM, fixed cells on coverslips were rinsed several times
with distilled water, dehydrated through an ethanol series and
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were examined in a JEOL JSM 5510 microscope. All EM supplies
were obtained from Agar Scientific.
Flow cytometry
Cells were washed and stained in FACS buffer consisting of
phosphate-buffered saline (PBS), human IgG (10 mg/mL, Sigma),
1% fetal calf serum (Hyclone), and 0.01% sodium azide. Macro-
phages were detached using cold PBS containing 5 mM ethylene-
diamine tetraacetic acid, washed and stained for surface markers
on ice for 30 minutes. For intracellular staining, cells were fixed
in 2% formaldehyde, permeabilized with 0.2% saponin and
stained for 45 to 60 minutes. Cells were washed three times before
acquisition, and all antibodies were compared with an isotype-
matched control. Antibodies used included CD14-phycoerythrin
(PE) (clone MEM-18), CD4-fluorescein isothiocyanate (FITC)
(clone MEM-241), CD33-FITC (clone MD33.6) from Immuno-
tools, CD68-FITC (clone KiM7), TLR2-FITC (clone TLR2.3),
TLR4-FITC (clone HTA125) from AbD Serotec, and CD86-
FITC (clone 37301.111) from R&D. Data were analyzed using
FlowJo software and presented as histograms with antibody stain-
ing in black relative to isotype-matched control in gray. The per-
centage of cells expressing markers was determined by subtracting
the isotype background from the antibody staining percentage.
Protein expression levels were determined by dividing the geomet-
rical mean fluorescence intensity (MFI) of the antibody staining
with the MFI of the isotype control.
Transcriptome analysis
The transcriptional profile was evaluated in three independent cell
preparations using the GeneChip Human Gene 1.0 ST Array (Af-
fymetrix) containing a total ofw29,000 transcripts. For the esMC
and hES monocyte–derived macrophages (esMDM) samples,
RNA was purified from three different experiments using the
HUES-2 hES cell line. For the blood–derived monocytes (bMC)
samples, RNA was purified from three different donors. RNA
was extracted with the RNeasy minikit (Qiagen) and RNA quality
controlled by running samples on an Agilent Bioanalyser 2100.
RNA integrity numbers were in the range of 8.8 to 10. RNA label-
ing, hybridization, and array scanning were conducted at the Sir
Henry Wellcome Functional Genomic Facility at the University
of Glasgow and signal values were generated using the Robust
Multichip Average method [17]. Data sets from 11 human tissue
samples were obtained from the Affymetrix Web site. Correlation
analysis was done using the Affymetrix Expression Console soft-
ware. Statistical analysis and hierarchical clustering were done
using the TM4 software [18].
Acetylated low-density lipoprotein endocytosis
Macrophages were washed with cold PBS and incubated for 1
hour at 37C with OPTIMEM medium alone or in the presence
of 100 mg/mL scavenger receptor ligand poly inosinic acid or con-
trol poly cytidylic acid. Medium was aspirated, and 2.85 mg/mL
acetylated low-density lipoprotein (acLDL) added for 1 hour at
37C. Cells were washed twice, analyzed by immunofluorescence
microscopy and subsequently detached, fixed in 2% formaldehyde
and analyzed by flow cytometry. Ratio of endocytosis uptake was
calculated by dividing the MFI with the background signal from
cells cultured without acLDL.Zymosan phagocytosis
Zymosan yeast particles were opsonized with 25% non-heat–
inactivated human pooled serum (UK National Blood Bank) for
30 minutes at 37C. Zymosan was added at a ratio of 50 particles
per cell, to macrophages cultured on 13 mm2 glass coverslips, and
incubated for 45 minutes at 37C. Cells were washed twice in PBS
before TEM. Phagocytosis was quantified by manual counting the
number of particles observed per cell section.
Cytokine and chemokine secretion
Human ES macrophages were incubated with 1 mg/mL lipopoly-
saccharide (LPS). Supernatants from cultures were harvested after
2, 8, and 10 hours and frozen at –20C until assayed. Human tu-
mor necrosis factor–a (5.9–95,949 pg/mL), IL-1ra (1.6–25,493
pg/mL), IL-1b (2.5–40,738 pg/mL), IL-6 (1.7–28,299 pg/mL),
IL-10 (1.5–23939 pg/mL), IL-12(p70) (2.7–44,499 pg/mL),
interferon-inducible protein 10 (3.3–53,434 pg/mL), monocyte
chemotactic protein-1 (2.0–32,695 pg/mL), and eotaxin (0.2–
2763 pg/mL), were measured using a tailored multiplex cytokine
assay system (Bio-Rad Laboratories Hercules, CA, USA) [19].
Data analysis was carried out using Bio-Plex Manager software
(Bio-Rad Laboratories) with a 5-parametric-curve fitting.
Macrophage activation with IFN-g and IL-4
Macrophages were activated with either 20 U/mL or 200 U/mL
IFN-g (R&D), or 20 ng/mL IL-4 (R&D) for 72 hours. The effect
of activation was evaluated by quantifying changes in surface re-
ceptor expression of major histocompatibility complex (MHC)
class II and mannose receptor by flow cytometry.
Results
A three-step method for the
differentiation of hES cells into monocytes
Following detachment of hES cells from feeder cells, hES
cells aggregate in suspension cultures to form structures
known as embryoid bodies (EBs), which are composed of
cells from all three germ layers [20]. To generate EBs,
hES cells maintained on mouse embryo fibroblasts (MEF)
were detached from MEFs and cultured in suspension for
3 days in hES medium (Fig. 1A, Step 1). For the directed
differentiation into monocytes (Fig. 1A, Step 2), EBs
were plated onto plastic and cultured in serum-containing
medium supplemented with human recombinant M-CSF
and IL-3. Monocyte-like cells were first observed
migrating from the EBs and interacting with the adjacent
EB-derived stroma (Fig. 1A, Step 3). These cells, which
we refer to as hES-monocytes (esMCs), were harvested
from the supernatant of cultures, have a ruffled membrane,
high cytoplasm-to-nucleus ratio and typically an indented
nucleus (Fig. 1B and 1C). esMCs consisted of a single,
homogenous cell population based on morphology
(Fig. 1B), the cell scatter properties (Fig. 1D and
Suppl. Fig. 1) and CD14-expression profile (Fig. 1E and
Suppl. Fig. 1). Furthermore, esMCs were phenotypically
similar to blood monocytes isolated by positive selection
for CD14, and expressed various leukocyte and monocyte
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and CD54 (Suppl. Fig. 1). esMC did not express markers of
dendritic cells such as CD83, integrin aE (CD103) or of
blood stem cells such as CD34 (Suppl. Fig. 1). esMC purity,
as determined by CD14-expression, was 90.9% 6 2.5%
(mean 6 SEM, n 5 16) from cells derived from both
hES cell line KCL002 (97.5% 6 0.8%, n 5 2) and
HUES-2 (90.0% 6 2.8%, n 5 14). esMCs were produced
after a lag period (mean 18.7 6 7.7 days, n5 19), followed
by a rapid production phase and a subsequent period of con-
tinuous lower level production that lasted for several
months (Fig. 1F and Suppl. Fig. 1). Average esMC yield
was 8.7  106 6 4.0  106 (n 5 9) cells with an average
of 3.4  105 6 2.0  105 esMCs produced per EB. In vivo,
monocytes differentiate into macrophages when leaving the
circulation and migrating into specific tissues, a process
that is mimicked in vitro by allowing blood monocytes to
adhere and differentiate on tissue-culture treated plastic.
To test if esMCs could differentiate into esMDMs, we cul-
tured esMCs on tissue-culture treated plastic for 6 days with
M-CSF and evaluated cellular morphology and the expres-
sion of CD68, a marker expressed by the majority of human
tissue macrophages [21,22] and CD163, a scavenger recep-
tor expressed by M-CSF polarized macrophages [23]. We
found that esMCs differentiated into a homogenous adher-
ent and elongated macrophage population with a uniform
expression of both CD68 and CD163 (Fig. 1G), similar to
blood monocyte–derived macrophages (bMDM) cultured
in M-CSF ([24] and data not shown). esMDM were
phenotypically similar to bMDM and had downregulated
CD14, expressed M-CSF receptor, Fc-g receptor (FcgR)
Type I (CD64), FcgR Type II (CD32), and CCR5 (Suppl.
Fig. 1).
Transcriptome analysis of esMCs
and esMDMs reveal a distinct myeloid gene signature
To better characterize the esMCs and esMDMs, we studied
the global expression of mRNA transcripts in these two cell
types and compared the expression pattern relative to that
of primary adult bMCs and several major human tissue
samples including spleen, thyroid, brain, breast, heart, kid-
ney, liver, pancreas, prostate, skeletal muscle, and testis.
We found that expression patterns in esMCs, esMDMs,
and bMCs correlated significantly (r-value O 0.9)
(Fig. 2A). We also found that while several of the tissue
samples correlated significantly, only the spleen tissue
samples correlated significantly (r-value O 0.9) with the
esMCs, esMDMs, and bMCs (Fig. 2A). Since human spleen
is highly enriched in mononuclear phagocytes, such as
macrophages (about 16%) [25], the data suggest that the
esMCs and esMDMs are similar to primary adult mononu-
clear phagocytes.
We next evaluated genes differentially expressed in
esMCs, esMDMs, bMCs, and the spleen tissue sample com-
pared with the remaining tissue samples. We found that9.3% of the total genes (2699 genes) were differentially
expressed and that 5.1% of the genes (1462 genes) repre-
sented a distinct myeloid signature. A selection of
myeloid-related genes is shown in Figure 2B and we have
confirmed the expression of several of these genes at the
protein level by flow cytometry (Fig. 2C and data not
shown). We found that esMCs and esMDMs expressed
well-defined markers of the mononuclear phagocyte system
including transcription factors PU-1 (SPI1) and C/EBPa
[6,26], membrane receptors EMR1 and EMR2 [2,27–29],
MPEG1 [30], CD1c [31], CD4 [32], CD18 (integrin b2),
CD32 (FcgRII), CD33 (SIGLEC-3) [33,34], CD68 [21,22],
and enzymes including the cathepsins [35], and serine
carboxypeptidase (CPVL) [36,37]. In addition, esMCs and
esMDMs expressed several genes involved in the recognition
of the endotoxin LPS such as CD14, TLR2, TLR4, and LY86
(MD-2) [38,39].
Together, the data suggest that esMCs and esMDMs
share a distinct myeloid gene signature with primary adult
bMCs and spleen cells.
esMCs differentiate into functional macrophages
Mononuclear phagocytes are phenotypically and func-
tionally heterogeneous as a result of cellular differentia-
tion, tissue distribution and responsiveness to various
stimuli [3]. However, adult primary macrophages share
functions including the ability to endocytose, phagocy-
tose, secrete cytokines, and responsiveness to different
activation signals. In order to test whether esMCs could
differentiate into functional macrophages, we differenti-
ated esMCs into esMDM and carried out various func-
tional assays.
To test whether esMDMs could endocytose, we cocul-
tured cells with fluorescently labeled acLDL. We found
that esMDMs could endocytose acLDL nearly as efficiently
as bMDM cultured under identical conditions (esMDM
14.9-fold vs bMDM 29.7-fold; Fig. 3A). We confirmed
that endocytosis was mediated by scavenger receptors, be-
cause uptake could be inhibited specifically by a scavenger
receptor inhibitor (Fig. 3A).
To test whether esMDMs could phagocytose, we cul-
tured cells with yeast particles opsonized with human se-
rum. We found that esMDMs were highly phagocytic
with 89% of cells ingesting one particle or more, compared
to 79% of bMDMs (Fig. 3B).
To test whether esMDMs could recognize and respond to
a bacterial stimulus, we stimulated esMDMs with the endo-
toxin LPS, a bacterial ligand for the receptors CD14, TLR2,
TLR4 and LY86 (MD-2) [38,39], which were found to be
expressed in the esMC and esMDM (Fig. 2 and data not
shown). We found that esMDMs produced high levels of tu-
mor necrosis factor–a (16.8 6 7.4 ng/mL), IL-10 (11.1 6
5.6 ng/mL), IL-6 (O8.3 ng/mL), IL-1ra (5.1 6 0.8 ng/
mL), monocyte chemotactic protein-1 (O14.1 ng/mL)
and interferon-inducible protein 10 (O46.5 ng/mL) after
1172 K.R. Karlsson et al./ Experimental Hematology 2008;36:1167–1175Figure 2. Transcriptome analysis of human embryonic stem (hES) monocytes (esMCs) and hES monocyte–derived macrophages (esMDM) reveal a distinct
myeloid gene signature. Transcriptome analysis of esMCs using the GeneChip Human Gene 1.0 ST Array (Affymetrix) containing a total ofw29,000 tran-
scripts. (A) Pearson correlation analysis of RNA expression levels corresponding to esMCs, hES monocyte-derived macrophages (esMDMs), blood–derived
monocytes (bMCs), and 11 other major tissues samples. Pearson correlation levelsO0.9 are visualized in red, and!0.9 in blue. (B) Hierarchical clustering
of 42 selected genes expressed in the esMC, esMDM, bMC, and spleen tissue samples. The 42 selected genes were obtained by performing a Euclidian
distance complete hierarchical clustering with an adjusted Bonferroni corrected p value!0.05. (C) Confirmation of expression data of six selected proteins
by flow cytometry.
1173K.R. Karlsson et al./ Experimental Hematology 2008;36:1167–1175Figure 3. Human embryonic stem (hES) monocytes (esMCs) differentiate into functional macrophages. (A) hES monocyte–derived macrophages (esMDM)
endocytose acetylated low-density lipoprotein (LDL). esMDMs and blood monocyte–derived macrophages (bMDM) were pretreated in medium alone, with
the scavenger receptor inhibitor poly inosinic acid, or control poly cytidylic acid and cells incubated with acetylated LDL. Images show immunofluorescence
with the corresponding phase-contrast image inserted. Inserted values show ratio of endocytosis uptake calculated by dividing the mean fluorescence intensity
(MFI) with the background signal from cells cultured without acetylated low-density lipoprotein (acLDL). (B) esMDMs phagocytose opsonized yeast par-
ticles. esMDMs and bMDMs were incubated with zymosan particles opsonized with human serum at a 1:50 cell-to-particle ratio. Frequency distribution
histogram show number of particles per TEM section comparing esMDMs (in black) with bMDMs (in gray). Inserted images show binding and internali-
zation in esMDMs by SEM (top) and TEM (bottom). Scale bar units are in mm. Results are representative of two separate experiments. (C) esMDMs upre-
gulate major histocompatibility complex (MHC) class II and mannose receptors after alternative activation with interleukin (IL)-4. esMDMs and bMDMs
were cultured in media alone or activated with interferon (IFN)-g (20 U/mL) or IL-4 (20 ng/mL) for 72 hours and assessed for MHC class II and mannose
receptor surface expression by flow cytometry. Histograms show antibody staining (in black) relative to isotype-matched control (in gray). Inserted values
show the ratio of surface receptor expression relative to isotype-matched control. (D) esMDMs produce chemokines and cytokines in response to lipopoly-
saccharide (LPS). esMDMs were cultured with LPS (1 mg/mL) and supernatants harvested after 2, 8, and 10 hours of stimulation and assessed for cytokine
and chemokine production. Culture media contained less than the lower detection limit for all proteins tested. Results are mean values from experimental
triplicates.10 hours of LPS stimulation (Fig. 3D). esMDM did not pro-
duce IL-1b, eotaxin or IL-12(p70).
To test whether esMDMs could be activated along both
the classical and alternative pathways [40], we cultured
cells in the presence of the T cell cytokines IFN-g or IL-
4 and evaluated the surface expression levels of MHC class
II and mannose receptor. We found that esMDMs, like
bMDM, upregulated surface expression of MHC class II af-
ter both IFN-g and IL-4 activation, while only IL-4 activa-
tion increased mannose receptor expression (Fig. 3D).
In summary, we have developed an efficient method to
produce hES-derived monocytes that differentiate into fully
functional macrophages that can be used as a tool to study
monocyte and macrophage development and biology.Discussion
The human mononuclear phagocyte system remains poorly
understood due to limitations in current technologies.
Methods for obtaining human primary myeloid progenitors,
monocytes and macrophages for in vitro studies are incon-
sistent and differ in cell yield, purity, and activation status
of cells [7]. Furthermore, primary monocytes and macro-
phages are inherently difficult to transfect. This limits the
ability to genetically manipulate monocytes and macro-
phages to investigate their development and biology. Plu-
ripotent ES cells offer an attractive alternative to
overcome these problems and mES-derived mononuclear
phagocytes have been successfully produced and studied
in vitro [8–12]. Current methods using similar approaches
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cultures with other cell lines, the use of complex cytokine
cocktails and additional purification steps. For example,
the coculture of undifferentiated hES cells with mouse
bone marrow cells or yolk sac endothelial cells produces
hematopoietic progenitors that can be isolated by selecting
for various markers and further differentiated into defined
hematopoietic lineages [41]. Similarly, directed differentia-
tion of hES using multiple cytokines also produces hemato-
poietic progenitors that can be differentiated into most
hematopoietic lineages including erythroid, lymphoid, and
myeloid cells [13,14,42–45].
In this study, we report a much simpler and highly effi-
cient three-step method for the differentiation of hES cells
into a homogenous population of esMCs. We found that
esMCs were produced after approximately 18 days of di-
rected differentiation in medium containing just two exog-
enous growth factors, and esMC continued to be produced
for several months when growth factors were replaced.
We have validated this method using different hES cell
lines derived from independent laboratories and confirmed
esMC purity by morphology, scatter properties, and recep-
tor expression profiles. In agreement with the adult mono-
nuclear phagocyte system, the esMCs differentiated into
functional macrophages and shared a distinct myeloid
gene signature with both primary adult bMCs and spleen
cells. Together, the data suggest that the method provides
a good model system to investigate mononuclear phago-
cytes in vitro and could also be useful in identifying novel
markers of the human mononuclear phagocyte system [2].
esMDMs were found to be functionally comparable to in
vitro M-CSF–polarized adult bMDMs and shared many
properties with these cells including morphology [24],
expression of CD163 [23], high capacity to phagocytose
and endocytose [46], and secretion of IL-10 but not IL-
12 [23,47]. Interestingly, recent work has shown that
M-CSF–polarized bMDMs share these functional character-
istics with human peritoneal macrophages [46]. Because
esMDMs maintain a stable and functional phenotype with
time and the method can be scaled up to produce large num-
ber of cells, it will be particularly useful for investigating
macrophage-specific functions in various diseases including
atherosclerosis, sepsis, cancer, tuberculosis, and HIV-1.
In summary, we have developed an efficient method to
produce esMCs that differentiate into functional macro-
phages which should prove useful in answering experimen-
tal questions regarding human monocyte and macrophage
development and biology especially when combined with
specific genetic modification of the hES cells.
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